Alivus Life Sciences balance sheet

As of Sep 2026

Total assets: ₹4,342cr+19.3% on Sep 2025
Shareholders' equity: ₹3,631cr+20.4% on Sep 2025
Total debt: ₹0.0crNo figure a year before
Cash and investments: ₹1,012cr+55.0% on Sep 2025

₹ crore except per share

Tap a line for its trend	H1 FY27Sep 2026	FY24Mar 2024	FY23Mar 2023	FY22Mar 2022

Non-current assets
	1,011	795	775	585
	408	101	49.4	91.7
	29.2	10.1	5.7	10.4
	7.0	4.8	12.3	—
	0.1	0.1	0.1	0.1
	8.8	11.0	8.2	5.6
	8.9	11.1	8.3	5.6
	13.9	—	1.3	—
	1,477	934	852	706
Current assets
	783	667	604	516
	986	—	—	—
	988	765	807	673
	25.4	301	284	512
	0.1	0.2	25.6	0.0
	1.5	90.4	70.9	5.9
	2,001	1,157	1,187	1,192
	80.7	92.0	59.1	56.8
	2,865	1,916	1,850	1,765
	4,342	2,850	2,702	2,471
Equity
	24.6	24.5	24.5	24.5
	3,607	2,308	2,114	2,030
	3,631	2,332	2,138	2,054
	3,631	2,332	2,138	2,054
Liabilities
	44.5	—	—	—
	44.5	—	—	—
	37.8	15.8	—	—
	64.7	48.8	42.4	31.5
	147	79.3	59.5	32.7
	427	—	—	—
	67.5	—	—	—
	495	—	—	—
	19.8	12.0	15.5	14.4
	29.0	—	—	—
	20.1	15.4	29.7	3.4
	564	439	504	384
	711	518	564	417
	4,342	2,850	2,702	2,471
Trade payables — MSME split
	23.1	—	—	—
	404	—	—	—

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ALIVUS₹1,397.40

Alivus Life Sciences Ltd.

· Pharma & Health

₹ CrorePeersDIVISLAB AARTIDRUGS AKUMS AGARWALEYE APLLTD ADVENZYMES AARTIPHARM CORONA

View

In ₹ Crore except Per Share As of	FY22 31/03/2022	FY23 31/03/2023	FY24 31/03/2024	Last 12M 30/09/2026
Non-current Assets
+ Property, Plant & Equipment	584.6	774.9	795.0	1,010.5
+ Capital Work-in-Progress	91.7	49.4	101.2	407.6
+ Other Intangibles	10.4	5.7	10.1	29.2
+ Intangibles under Development	—	12.3	4.8	7.0
+ Non-current Investments	0.1	0.1	0.1	0.1
+ Other Non-current Financial Assets	5.6	8.2	11.0	8.8
Non-current Financial Assets	5.6	8.3	11.1	8.9
+ Other Non-current Assets	—	1.3	—	13.9
Total Non-current Assets	706.4	851.8	934.4	1,477.1
Current Assets
+ Inventories	516.2	604.2	666.6	782.8
+ Current Investments	—	—	—	986.2
+ Trade Receivables	673.5	806.8	765.4	988.2
+ Cash & Cash Equivalents	512.2	283.8	301.4	25.4
+ Other Bank Balances	0.0	25.6	0.2	0.1
+ Other Current Financial Assets	5.9	70.9	90.4	1.5
Current Financial Assets	1,191.6	1,187.1	1,157.4	2,001.4
+ Other Current Assets	56.8	59.1	92.0	80.7
Total Current Assets	1,764.6	1,850.3	1,916.0	2,864.8
Total Assets	2,471.0	2,702.1	2,850.4	4,341.9
Equity
+ Equity Share Capital	24.5	24.5	24.5	24.6
+ Other Equity / Reserves	2,029.8	2,113.7	2,307.8	3,606.7
Equity — Owners of Parent	2,054.3	2,138.2	2,332.3	3,631.3
Total Equity	2,054.3	2,138.2	2,332.3	3,631.3
Liabilities
+ Other Non-current Financial Liab	—	—	—	44.5
Non-current Financial Liabilities	—	—	—	44.5
+ Provisions — Non-current	—	—	15.8	37.8
+ Deferred Tax Liabilities	31.5	42.4	48.8	64.7
Non-current Liabilities	32.7	59.5	79.3	146.9
+ Trade Payables	—	—	—	427.3
+ Other Current Financial Liab	—	—	—	67.5
Current Financial Liabilities	—	—	—	494.8
+ Provisions — Current	14.4	15.5	12.0	19.8
+ Current Tax Liabilities	—	—	—	29.0
+ Other Current Liabilities	3.4	29.7	15.4	20.1
Current Liabilities	384.0	504.4	438.8	563.7
Total Liabilities	416.7	563.9	518.1	710.7
Total Equity & Liabilities	2,471.0	2,702.1	2,850.4	4,341.9
Trade Payables — MSME split
+ Dues to Micro & Small — Current	—	—	—	23.1
+ Dues to Other Creditors — Current	—	—	—	404.2

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY24 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.